Wooridul Huebrain Limited (118000.KS)
KRW 316.0
(-1.25%)
KRW 316.0
(-1.25%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 13.92 Billion KRW | 106.05% |
| 2022 | 6.75 Billion KRW | -1.79% |
| 2021 | 6.88 Billion KRW | 49.0% |
| 2020 | 4.61 Billion KRW | 5.34% |
| 2019 | 4.38 Billion KRW | -48.95% |
| 2018 | 8.58 Billion KRW | 0.97% |
| 2017 | 8.5 Billion KRW | 67.2% |
| 2016 | 5.08 Billion KRW | -39.6% |
| 2015 | 8.42 Billion KRW | -7.9% |
| 2014 | 9.14 Billion KRW | 27.7% |
| 2013 | 7.16 Billion KRW | 25.82% |
| 2012 | 5.69 Billion KRW | -49.51% |
| 2011 | 11.27 Billion KRW | 28.98% |
| 2010 | 8.74 Billion KRW | 3039.97% |
| 2009 | 278.35 Million KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | -1.46 Billion KRW | -116.87% |
| 2024 Q2 | 1.14 Billion KRW | 176.88% |
| 2023 FY | 13.92 Billion KRW | 106.05% |
| 2023 Q2 | 1.61 Billion KRW | -46.77% |
| 2023 Q1 | 3.02 Billion KRW | 106.16% |
| 2023 Q4 | 8.68 Billion KRW | 656.97% |
| 2023 Q3 | -1.55 Billion KRW | -196.74% |
| 2022 FY | 6.75 Billion KRW | -1.79% |
| 2022 Q2 | 1.58 Billion KRW | -13.9% |
| 2022 Q1 | 1.84 Billion KRW | -0.33% |
| 2022 Q3 | 1.85 Billion KRW | 16.82% |
| 2022 Q4 | 1.46 Billion KRW | -20.84% |
| 2021 Q3 | 1.71 Billion KRW | -13.67% |
| 2021 Q1 | 1.32 Billion KRW | 53.46% |
| 2021 FY | 6.88 Billion KRW | 49.0% |
| 2021 Q2 | 1.98 Billion KRW | 49.87% |
| 2021 Q4 | 1.85 Billion KRW | 7.86% |
| 2020 Q4 | 864.23 Million KRW | -28.91% |
| 2020 Q2 | 1.28 Billion KRW | 1.79% |
| 2020 Q1 | 1.25 Billion KRW | 826.87% |
| 2020 FY | 4.61 Billion KRW | 5.34% |
| 2020 Q3 | 1.21 Billion KRW | -5.06% |
| 2019 Q1 | 1.49 Billion KRW | -9.6% |
| 2019 FY | 4.38 Billion KRW | -48.95% |
| 2019 Q3 | 1.22 Billion KRW | -20.38% |
| 2019 Q4 | 135.71 Million KRW | -88.89% |
| 2019 Q2 | 1.53 Billion KRW | 2.78% |
| 2018 Q1 | 2.84 Billion KRW | -3.39% |
| 2018 Q4 | 1.65 Billion KRW | -19.94% |
| 2018 Q3 | 2.06 Billion KRW | 1.72% |
| 2018 FY | 8.58 Billion KRW | 0.97% |
| 2018 Q2 | 2.02 Billion KRW | -28.81% |
| 2017 FY | 8.5 Billion KRW | 67.2% |
| 2017 Q2 | 1.76 Billion KRW | 65.83% |
| 2017 Q3 | 2.73 Billion KRW | 54.88% |
| 2017 Q4 | 2.94 Billion KRW | 7.9% |
| 2017 Q1 | 1.06 Billion KRW | -31.19% |
| 2016 Q1 | 1.32 Billion KRW | -26.4% |
| 2016 FY | 5.08 Billion KRW | -39.6% |
| 2016 Q4 | 1.54 Billion KRW | 41.95% |
| 2016 Q3 | 1.08 Billion KRW | -3.82% |
| 2016 Q2 | 1.13 Billion KRW | -14.28% |
| 2015 Q4 | 1.79 Billion KRW | -29.8% |
| 2015 Q3 | 2.55 Billion KRW | 40.41% |
| 2015 FY | 8.42 Billion KRW | -7.9% |
| 2015 Q1 | 2.25 Billion KRW | -26.75% |
| 2015 Q2 | 1.82 Billion KRW | -19.12% |
| 2014 Q1 | 2.01 Billion KRW | -36.4% |
| 2014 FY | 9.14 Billion KRW | 27.7% |
| 2014 Q4 | 3.07 Billion KRW | 41.34% |
| 2014 Q3 | 2.17 Billion KRW | 15.57% |
| 2014 Q2 | 1.88 Billion KRW | -6.65% |
| 2013 Q1 | 1.41 Billion KRW | 24.91% |
| 2013 Q3 | 1.13 Billion KRW | -21.89% |
| 2013 FY | 7.16 Billion KRW | 25.82% |
| 2013 Q2 | 1.44 Billion KRW | 2.64% |
| 2013 Q4 | 3.16 Billion KRW | 180.07% |
| 2012 FY | 5.69 Billion KRW | -49.51% |
| 2012 Q2 | 1.84 Billion KRW | 31.66% |
| 2012 Q1 | 1.4 Billion KRW | -52.08% |
| 2012 Q4 | 1.13 Billion KRW | -13.93% |
| 2012 Q3 | 1.31 Billion KRW | -28.97% |
| 2011 Q2 | 4.61 Billion KRW | 140.85% |
| 2011 Q4 | 2.93 Billion KRW | 61.54% |
| 2011 FY | 11.27 Billion KRW | 28.98% |
| 2011 Q1 | 1.91 Billion KRW | -24.73% |
| 2011 Q3 | 1.81 Billion KRW | -60.7% |
| 2010 Q3 | 2.78 Billion KRW | 27.14% |
| 2010 Q2 | 2.19 Billion KRW | 80.43% |
| 2010 Q1 | 1.21 Billion KRW | 0.0% |
| 2010 FY | 8.74 Billion KRW | 3039.97% |
| 2010 Q4 | 2.54 Billion KRW | -8.63% |
| 2009 FY | 278.35 Million KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Daewoong Co., Ltd. | 728.62 Billion KRW | 98.089% |
| PharmGen Science, Inc. | 87.07 Billion KRW | 84.009% |